胆酶:酶活性,参与癌症和其他疾病,抑制剂
Jan Korbecki1,2, Mateusz Bosiacki2, Patrycja Kupnicka2
1Department of Anatomy and Histology, Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland.
International journal of cancer
|December 11, 2024
概括
胆酶 (CHKα和CHKβ) 通过改变瘤代谢,在癌细胞增殖中起着至关重要的作用. 本综述探讨了它们的功能,在各种癌症中的临床相关性,以及CHKα抑制剂作为抗瘤药物的潜力.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 瘤的新陈代谢与健康组织不同,特别是通过胆激酶 (CHKα和CHKβ) 的胆酸化.
- 这一过程启动了类胆的合成,影响了癌细胞的行为.
- 在关于CHK在癌症中的作用和其抑制剂的抗瘤潜力的综合性审查中存在差距.
研究的目的:
- 审查CHKα和CHKβ的酶和非酶性质.
- 阐明它们在癌症过程中的参与,特别是癌症的扩散.
- 讨论CHKα抑制剂的临床方面和治疗潜力.
主要方法:
- 对CHKα和CHKβ的酶和非酶性质的文献综述.
- 分析CHK在癌细胞增殖中的作用.
- 检查跨多种癌症类型的临床数据.
- 评估CHKα抑制剂作为潜在的抗癌药物.
主要成果:
- CHKα和CHKβ是癌症过程中不可或缺的组成部分,特别是扩散.
- 胆酶与各种癌症有关,包括胰腺癌,卵巢癌,肺癌,乳腺癌和血液性恶性瘤.
- CHKα抑制剂显示出作为抗瘤疗法的前景,尽管尚未在临床试验中.
结论:
- 了解CHKα和CHKβ的功能对于癌症研究至关重要.
- CHKα抑制剂代表了癌症治疗的潜在新途径.
- 胆激酶在非癌症疾病中也有影响.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


